Assessment of the impact of nonavalent human papillomavirus vaccine on disease clearance time in women with active infection
Revista Brasileira de Ginecologia e Obstetrícia · 29.05.2026 · 48
DOI: 10.61622/rbgo/2026rbgo17 ↗Kurz gefasst
Fachartikel in der Zeitschrift Revista Brasileira de Ginecologia e Obstetrícia, erschienen am 29.05.2026. Verfasst von Nina Grillo und 2 weiteren Autor:innen. Beteiligte Einrichtung: Unidade Local de Saúde do Alto Alentejo Hospital Santa Luzia de Elvas Elvas Portugal Hospital Santa Luzia de Elvas, Unidade Local de Saúde do Alto Al…. Hauptthemen laut MEDLINE: Papillomavirus Infections, Papillomavirus Vaccines, Uterine Cervical Neoplasms, Human Papillomavirus Viruses. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objective
Human papillomavirus (HPV) is a leading cause of cervical cancer (CC) worldwide. There is growing interest in the potential role of HPV vaccination as adjuvant measure in patients with active infection. This study aimed to assess whether the nonavalent HPV vaccine (9vHPV) promotes faster disease clearance in women with low-grade (LGD) and high-grade disease (HGD).
Methods
Retrospective study including women aged 25–60 years who began follow-up in 2018 at a central Portuguese hospital after referral through organized CC screening. A total of 126 patients with HGD (69 vaccinated, 57 unvaccinated) and 277 with LGD (131 vaccinated, 146 unvaccinated) at baseline were followed with HPV cotesting (HPV test + cervical cytology) at 12, 18, 24, 36, and 48 months. Disease clearance was defined as the first negative cotest result. Kaplan-Meier curves and the Log Rank test were used to compare time to clearance between groups.
Results
Among HGD patients, the vaccinated group showed a shorter mean time to disease clearance (17.4 months; 95% CI: 14.88–19.93) compared to the unvaccinated group (20.2 months; 95% CI: 17.07–23.34), although the difference was not statistically significant (p=0.228). In the LGD group, both vaccinated and unvaccinated patients had similar mean clearance times (25.9 months; 95% CI: 23.44–28.43 vs. 26.9 months; 95% CI: 24.41–29.37), also lacking statistical significance (p=0.637).
Conclusion
Main findings suggest a negligible effect of 9vHPV in significantly reducing time to clearance in patients with active infection. Further research is needed to clarify its role in secondary prevention strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unidade Local de Saúde do Alto Alentejo Hospital Santa Luzia de Elvas Elvas Portugal Hospital Santa Luzia de Elvas, Unidade Local de Saúde do Alto Alentejo, Elvas, Portugal.
- Unidade Local de Saúde de Braga Hospital de Braga Braga Portugal Hospital de Braga, Unidade Local de Saúde de Braga, Braga, Portugal.
ORCID-Profile: Nina Grillo, Rita Almendra, Cátia Correia
Zitieren
APA
Grillo, N., Almendra, R., & Correia, C. (2026). Assessment of the impact of nonavalent human papillomavirus vaccine on disease clearance time in women with active infection. Revista Brasileira de Ginecologia e Obstetrícia, 48. https://doi.org/10.61622/rbgo/2026rbgo17
Vancouver
Grillo N, Almendra R, Correia C. Assessment of the impact of nonavalent human papillomavirus vaccine on disease clearance time in women with active infection. Revista Brasileira de Ginecologia e Obstetrícia. 2026;48. doi:10.61622/rbgo/2026rbgo17
BibTeX
@article{Grillo2026,
author = {Grillo, Nina and Almendra, Rita and Correia, Cátia},
title = {Assessment of the impact of nonavalent human papillomavirus vaccine on disease clearance time in women with active infection},
journal = {Revista Brasileira de Ginecologia e Obstetrícia},
year = {2026},
volume = {48},
doi = {10.61622/rbgo/2026rbgo17}
}
EUVIMED